nodes	percent_of_prediction	percent_of_DWPC	metapath
Entacapone—COMT—Neurotransmitter Clearance In The Synaptic Cleft—ALDH2—esophageal cancer	0.0399	0.109	CbGpPWpGaD
Entacapone—UGT1A9—Nicotine Metabolism—CYP2A6—esophageal cancer	0.0283	0.0775	CbGpPWpGaD
Entacapone—UGT1A9—Irinotecan Pathway—ABCC2—esophageal cancer	0.0179	0.0492	CbGpPWpGaD
Entacapone—COMT—Estrogen metabolism—CYP1B1—esophageal cancer	0.0158	0.0433	CbGpPWpGaD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—ALDH3A1—esophageal cancer	0.0148	0.0406	CbGpPWpGaD
Entacapone—UGT1A9—Estrogen metabolism—CYP1B1—esophageal cancer	0.00946	0.0259	CbGpPWpGaD
Entacapone—UGT1A9—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00926	0.0254	CbGpPWpGaD
Entacapone—UGT1A9—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.00741	0.0203	CbGpPWpGaD
Entacapone—COMT—Phase II conjugation—GSTO1—esophageal cancer	0.00718	0.0197	CbGpPWpGaD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—NFE2L2—esophageal cancer	0.00644	0.0177	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—ALDH3A1—esophageal cancer	0.00588	0.0161	CbGpPWpGaD
Entacapone—COMT—Phase II conjugation—GSTT1—esophageal cancer	0.00557	0.0153	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—ADH7—esophageal cancer	0.00554	0.0152	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—BLVRB—esophageal cancer	0.00524	0.0144	CbGpPWpGaD
Entacapone—UGT1A9—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.00492	0.0135	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—ADH1B—esophageal cancer	0.00486	0.0133	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—CYP26A1—esophageal cancer	0.00452	0.0124	CbGpPWpGaD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—CYP1B1—esophageal cancer	0.00447	0.0122	CbGpPWpGaD
Entacapone—COMT—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00446	0.0122	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—PRDX1—esophageal cancer	0.00445	0.0122	CbGpPWpGaD
Entacapone—UGT1A9—Phase II conjugation—GSTO1—esophageal cancer	0.0043	0.0118	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—GSTO1—esophageal cancer	0.0042	0.0115	CbGpPWpGaD
Entacapone—COMT—Metapathway biotransformation—GSTO1—esophageal cancer	0.00414	0.0114	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—SLC39A6—esophageal cancer	0.00397	0.0109	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—ADH7—esophageal cancer	0.00379	0.0104	CbGpPWpGaD
Entacapone—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.00355	0.00558	CcSEcCtD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—BAX—esophageal cancer	0.00348	0.00954	CbGpPWpGaD
Entacapone—Urinary incontinence—Capecitabine—esophageal cancer	0.00348	0.00548	CcSEcCtD
Entacapone—Colitis—Capecitabine—esophageal cancer	0.00346	0.00544	CcSEcCtD
Entacapone—COMT—Biological oxidations—ALDH2—esophageal cancer	0.00342	0.00939	CbGpPWpGaD
Entacapone—Fluid retention—Capecitabine—esophageal cancer	0.00342	0.00538	CcSEcCtD
Entacapone—UGT1A9—Phase II conjugation—GSTT1—esophageal cancer	0.00334	0.00914	CbGpPWpGaD
Entacapone—Blood creatinine increased—Cisplatin—esophageal cancer	0.00332	0.00523	CcSEcCtD
Entacapone—UGT1A9—Biological oxidations—ADH7—esophageal cancer	0.00332	0.0091	CbGpPWpGaD
Entacapone—Oesophagitis—Capecitabine—esophageal cancer	0.00329	0.00518	CcSEcCtD
Entacapone—COMT—Biological oxidations—GSTT1—esophageal cancer	0.00326	0.00893	CbGpPWpGaD
Entacapone—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00324	0.0051	CcSEcCtD
Entacapone—COMT—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.00324	0.00888	CbGpPWpGaD
Entacapone—COMT—Biological oxidations—CYP2A6—esophageal cancer	0.00322	0.00883	CbGpPWpGaD
Entacapone—Cramp muscle—Cisplatin—esophageal cancer	0.00319	0.00503	CcSEcCtD
Entacapone—Mental disability—Capecitabine—esophageal cancer	0.00313	0.00492	CcSEcCtD
Entacapone—COMT—Biological oxidations—PTGS1—esophageal cancer	0.00305	0.00837	CbGpPWpGaD
Entacapone—COMT—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.00304	0.00832	CbGpPWpGaD
Entacapone—Phlebitis—Capecitabine—esophageal cancer	0.00304	0.00478	CcSEcCtD
Entacapone—Sleep disorder—Capecitabine—esophageal cancer	0.00302	0.00476	CcSEcCtD
Entacapone—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.00301	0.00473	CcSEcCtD
Entacapone—Hepatic function abnormal—Capecitabine—esophageal cancer	0.00299	0.00471	CcSEcCtD
Entacapone—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.00299	0.00471	CcSEcCtD
Entacapone—Sweating increased—Cisplatin—esophageal cancer	0.00299	0.0047	CcSEcCtD
Entacapone—Gastroenteritis—Capecitabine—esophageal cancer	0.00295	0.00464	CcSEcCtD
Entacapone—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.00295	0.00464	CcSEcCtD
Entacapone—Vascular purpura—Capecitabine—esophageal cancer	0.00292	0.0046	CcSEcCtD
Entacapone—UGT1A9—Biological oxidations—ADH1B—esophageal cancer	0.00291	0.00798	CbGpPWpGaD
Entacapone—Herpes simplex—Methotrexate—esophageal cancer	0.00291	0.00458	CcSEcCtD
Entacapone—Hepatic failure—Capecitabine—esophageal cancer	0.00291	0.00458	CcSEcCtD
Entacapone—Haemolytic anaemia—Capecitabine—esophageal cancer	0.0029	0.00456	CcSEcCtD
Entacapone—UGT1A9—PPAR Alpha Pathway—CCND1—esophageal cancer	0.00287	0.00787	CbGpPWpGaD
Entacapone—Hepatic enzyme increased—Methotrexate—esophageal cancer	0.00284	0.00446	CcSEcCtD
Entacapone—Hot flush—Capecitabine—esophageal cancer	0.0028	0.0044	CcSEcCtD
Entacapone—Menopausal symptoms—Capecitabine—esophageal cancer	0.00277	0.00436	CcSEcCtD
Entacapone—Inflammation—Methotrexate—esophageal cancer	0.00276	0.00435	CcSEcCtD
Entacapone—Atrial fibrillation—Capecitabine—esophageal cancer	0.00276	0.00434	CcSEcCtD
Entacapone—UGT1A9—NRF2 pathway—ABCC2—esophageal cancer	0.00275	0.00754	CbGpPWpGaD
Entacapone—Dermatitis bullous—Capecitabine—esophageal cancer	0.00274	0.00431	CcSEcCtD
Entacapone—Purpura—Capecitabine—esophageal cancer	0.00271	0.00427	CcSEcCtD
Entacapone—UGT1A9—Biological oxidations—CYP26A1—esophageal cancer	0.00271	0.00742	CbGpPWpGaD
Entacapone—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00269	0.00424	CcSEcCtD
Entacapone—Arthritis—Capecitabine—esophageal cancer	0.00269	0.00424	CcSEcCtD
Entacapone—Myocardial infarction—Cisplatin—esophageal cancer	0.00268	0.00422	CcSEcCtD
Entacapone—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00268	0.00422	CcSEcCtD
Entacapone—UGT1A9—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00267	0.00732	CbGpPWpGaD
Entacapone—Conjunctivitis—Cisplatin—esophageal cancer	0.00266	0.00418	CcSEcCtD
Entacapone—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00261	0.00412	CcSEcCtD
Entacapone—Pain in extremity—Capecitabine—esophageal cancer	0.00261	0.00412	CcSEcCtD
Entacapone—Diplopia—Capecitabine—esophageal cancer	0.00261	0.00412	CcSEcCtD
Entacapone—COMT—Biological oxidations—CYP1B1—esophageal cancer	0.0026	0.00711	CbGpPWpGaD
Entacapone—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00259	0.00408	CcSEcCtD
Entacapone—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00259	0.00407	CcSEcCtD
Entacapone—COMT—Metapathway biotransformation—CYP1B1—esophageal cancer	0.00256	0.00702	CbGpPWpGaD
Entacapone—UGT1A9—NRF2 pathway—NFE2L2—esophageal cancer	0.00256	0.00701	CbGpPWpGaD
Entacapone—UGT1A9—Biological oxidations—GSTO1—esophageal cancer	0.00252	0.0069	CbGpPWpGaD
Entacapone—Bradycardia—Cisplatin—esophageal cancer	0.0025	0.00393	CcSEcCtD
Entacapone—Urinary retention—Capecitabine—esophageal cancer	0.00249	0.00391	CcSEcCtD
Entacapone—UGT1A9—Metapathway biotransformation—GSTO1—esophageal cancer	0.00248	0.0068	CbGpPWpGaD
Entacapone—COMT—Neuronal System—GNG7—esophageal cancer	0.00248	0.0068	CbGpPWpGaD
Entacapone—Ataxia—Capecitabine—esophageal cancer	0.00246	0.00387	CcSEcCtD
Entacapone—Blood creatinine increased—Capecitabine—esophageal cancer	0.00245	0.00386	CcSEcCtD
Entacapone—COMT—Biological oxidations—CYP19A1—esophageal cancer	0.00244	0.00669	CbGpPWpGaD
Entacapone—Urinary tract disorder—Cisplatin—esophageal cancer	0.00242	0.00382	CcSEcCtD
Entacapone—COMT—Metapathway biotransformation—CYP19A1—esophageal cancer	0.00241	0.0066	CbGpPWpGaD
Entacapone—Urethral disorder—Cisplatin—esophageal cancer	0.00241	0.00379	CcSEcCtD
Entacapone—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00239	0.00376	CcSEcCtD
Entacapone—Visual impairment—Cisplatin—esophageal cancer	0.00236	0.00372	CcSEcCtD
Entacapone—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.00235	0.00371	CcSEcCtD
Entacapone—COMT—Neuronal System—ALDH2—esophageal cancer	0.00233	0.00638	CbGpPWpGaD
Entacapone—Gastritis—Capecitabine—esophageal cancer	0.00231	0.00364	CcSEcCtD
Entacapone—Muscular weakness—Capecitabine—esophageal cancer	0.00231	0.00363	CcSEcCtD
Entacapone—UGT1A9—PPAR Alpha Pathway—MYC—esophageal cancer	0.0023	0.00631	CbGpPWpGaD
Entacapone—Eye disorder—Cisplatin—esophageal cancer	0.00229	0.00361	CcSEcCtD
Entacapone—Cardiac disorder—Cisplatin—esophageal cancer	0.00228	0.00359	CcSEcCtD
Entacapone—Flushing—Cisplatin—esophageal cancer	0.00228	0.00359	CcSEcCtD
Entacapone—Dysphagia—Capecitabine—esophageal cancer	0.00226	0.00356	CcSEcCtD
Entacapone—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CRABP1—esophageal cancer	0.00222	0.00608	CbGpPWpGaD
Entacapone—Angina pectoris—Capecitabine—esophageal cancer	0.0022	0.00347	CcSEcCtD
Entacapone—Sweating increased—Capecitabine—esophageal cancer	0.0022	0.00347	CcSEcCtD
Entacapone—UGT1A9—NRF2 pathway—CYP2A6—esophageal cancer	0.0022	0.00603	CbGpPWpGaD
Entacapone—Alopecia—Cisplatin—esophageal cancer	0.00217	0.00341	CcSEcCtD
Entacapone—Hepatic failure—Methotrexate—esophageal cancer	0.00217	0.00341	CcSEcCtD
Entacapone—Malnutrition—Cisplatin—esophageal cancer	0.00214	0.00336	CcSEcCtD
Entacapone—Dysuria—Capecitabine—esophageal cancer	0.00211	0.00333	CcSEcCtD
Entacapone—Flatulence—Cisplatin—esophageal cancer	0.00211	0.00331	CcSEcCtD
Entacapone—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.0021	0.00331	CcSEcCtD
Entacapone—Weight increased—Capecitabine—esophageal cancer	0.00206	0.00324	CcSEcCtD
Entacapone—Muscle spasms—Cisplatin—esophageal cancer	0.00205	0.00323	CcSEcCtD
Entacapone—UGT1A9—Biological oxidations—ALDH2—esophageal cancer	0.00205	0.00562	CbGpPWpGaD
Entacapone—Weight decreased—Capecitabine—esophageal cancer	0.00204	0.00322	CcSEcCtD
Entacapone—Hyperglycaemia—Capecitabine—esophageal cancer	0.00204	0.00321	CcSEcCtD
Entacapone—Pneumonia—Capecitabine—esophageal cancer	0.00203	0.00319	CcSEcCtD
Entacapone—Vision blurred—Cisplatin—esophageal cancer	0.00201	0.00317	CcSEcCtD
Entacapone—Depression—Capecitabine—esophageal cancer	0.00201	0.00316	CcSEcCtD
Entacapone—Tremor—Cisplatin—esophageal cancer	0.002	0.00315	CcSEcCtD
Entacapone—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00199	0.00313	CcSEcCtD
Entacapone—Ill-defined disorder—Cisplatin—esophageal cancer	0.00198	0.00312	CcSEcCtD
Entacapone—Myocardial infarction—Capecitabine—esophageal cancer	0.00198	0.00311	CcSEcCtD
Entacapone—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00198	0.00311	CcSEcCtD
Entacapone—Urinary tract infection—Capecitabine—esophageal cancer	0.00196	0.00308	CcSEcCtD
Entacapone—Conjunctivitis—Capecitabine—esophageal cancer	0.00196	0.00308	CcSEcCtD
Entacapone—UGT1A9—Biological oxidations—GSTT1—esophageal cancer	0.00195	0.00535	CbGpPWpGaD
Entacapone—UGT1A9—Biological oxidations—CYP2A6—esophageal cancer	0.00193	0.00529	CbGpPWpGaD
Entacapone—Malaise—Cisplatin—esophageal cancer	0.00193	0.00303	CcSEcCtD
Entacapone—Haematuria—Capecitabine—esophageal cancer	0.00192	0.00302	CcSEcCtD
Entacapone—Leukopenia—Cisplatin—esophageal cancer	0.00191	0.00301	CcSEcCtD
Entacapone—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00191	0.003	CcSEcCtD
Entacapone—Epistaxis—Capecitabine—esophageal cancer	0.0019	0.00299	CcSEcCtD
Entacapone—Agranulocytosis—Capecitabine—esophageal cancer	0.00188	0.00296	CcSEcCtD
Entacapone—Convulsion—Cisplatin—esophageal cancer	0.00185	0.00291	CcSEcCtD
Entacapone—Bradycardia—Capecitabine—esophageal cancer	0.00184	0.0029	CcSEcCtD
Entacapone—Ataxia—Methotrexate—esophageal cancer	0.00183	0.00288	CcSEcCtD
Entacapone—UGT1A9—Biological oxidations—PTGS1—esophageal cancer	0.00183	0.00501	CbGpPWpGaD
Entacapone—Myalgia—Cisplatin—esophageal cancer	0.00182	0.00286	CcSEcCtD
Entacapone—Haemoglobin—Capecitabine—esophageal cancer	0.00182	0.00286	CcSEcCtD
Entacapone—Anxiety—Cisplatin—esophageal cancer	0.00181	0.00285	CcSEcCtD
Entacapone—Haemorrhage—Capecitabine—esophageal cancer	0.00181	0.00285	CcSEcCtD
Entacapone—Hepatitis—Capecitabine—esophageal cancer	0.00181	0.00285	CcSEcCtD
Entacapone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00181	0.00284	CcSEcCtD
Entacapone—Hypoaesthesia—Capecitabine—esophageal cancer	0.0018	0.00283	CcSEcCtD
Entacapone—Discomfort—Cisplatin—esophageal cancer	0.0018	0.00283	CcSEcCtD
Entacapone—Pharyngitis—Capecitabine—esophageal cancer	0.0018	0.00283	CcSEcCtD
Entacapone—Urinary tract disorder—Capecitabine—esophageal cancer	0.00179	0.00281	CcSEcCtD
Entacapone—Urethral disorder—Capecitabine—esophageal cancer	0.00177	0.00279	CcSEcCtD
Entacapone—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.00175	0.00276	CcSEcCtD
Entacapone—Oedema—Cisplatin—esophageal cancer	0.00174	0.00274	CcSEcCtD
Entacapone—Visual impairment—Capecitabine—esophageal cancer	0.00174	0.00274	CcSEcCtD
Entacapone—Erythema multiforme—Capecitabine—esophageal cancer	0.00171	0.00269	CcSEcCtD
Entacapone—Nervous system disorder—Cisplatin—esophageal cancer	0.00171	0.00269	CcSEcCtD
Entacapone—Thrombocytopenia—Cisplatin—esophageal cancer	0.00171	0.00269	CcSEcCtD
Entacapone—Skin disorder—Cisplatin—esophageal cancer	0.00169	0.00267	CcSEcCtD
Entacapone—Eye disorder—Capecitabine—esophageal cancer	0.00169	0.00266	CcSEcCtD
Entacapone—Hyperhidrosis—Cisplatin—esophageal cancer	0.00169	0.00265	CcSEcCtD
Entacapone—Cardiac disorder—Capecitabine—esophageal cancer	0.00168	0.00264	CcSEcCtD
Entacapone—Flushing—Capecitabine—esophageal cancer	0.00168	0.00264	CcSEcCtD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EP300—esophageal cancer	0.00167	0.00459	CbGpPWpGaD
Entacapone—Anorexia—Cisplatin—esophageal cancer	0.00166	0.00262	CcSEcCtD
Entacapone—Hypotension—Cisplatin—esophageal cancer	0.00163	0.00256	CcSEcCtD
Entacapone—Alopecia—Capecitabine—esophageal cancer	0.0016	0.00252	CcSEcCtD
Entacapone—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00159	0.0025	CcSEcCtD
Entacapone—Mental disorder—Capecitabine—esophageal cancer	0.00158	0.00249	CcSEcCtD
Entacapone—Malnutrition—Capecitabine—esophageal cancer	0.00157	0.00248	CcSEcCtD
Entacapone—Dysuria—Methotrexate—esophageal cancer	0.00157	0.00248	CcSEcCtD
Entacapone—Paraesthesia—Cisplatin—esophageal cancer	0.00157	0.00246	CcSEcCtD
Entacapone—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00156	0.00246	CcSEcCtD
Entacapone—UGT1A9—Biological oxidations—CYP1B1—esophageal cancer	0.00155	0.00426	CbGpPWpGaD
Entacapone—Dyspnoea—Cisplatin—esophageal cancer	0.00155	0.00245	CcSEcCtD
Entacapone—Flatulence—Capecitabine—esophageal cancer	0.00155	0.00244	CcSEcCtD
Entacapone—Erectile dysfunction—Methotrexate—esophageal cancer	0.00155	0.00244	CcSEcCtD
Entacapone—UGT1A9—NRF2 pathway—TGFBR2—esophageal cancer	0.00154	0.00423	CbGpPWpGaD
Entacapone—Dysgeusia—Capecitabine—esophageal cancer	0.00154	0.00243	CcSEcCtD
Entacapone—UGT1A9—Metapathway biotransformation—CYP1B1—esophageal cancer	0.00153	0.0042	CbGpPWpGaD
Entacapone—Back pain—Capecitabine—esophageal cancer	0.00152	0.0024	CcSEcCtD
Entacapone—UGT1A9—NRF2 pathway—HMOX1—esophageal cancer	0.00152	0.00417	CbGpPWpGaD
Entacapone—Decreased appetite—Cisplatin—esophageal cancer	0.00152	0.00239	CcSEcCtD
Entacapone—Muscle spasms—Capecitabine—esophageal cancer	0.00151	0.00238	CcSEcCtD
Entacapone—Pneumonia—Methotrexate—esophageal cancer	0.00151	0.00238	CcSEcCtD
Entacapone—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00151	0.00237	CcSEcCtD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.0015	0.00411	CbGpPWpGaD
Entacapone—Depression—Methotrexate—esophageal cancer	0.0015	0.00235	CcSEcCtD
Entacapone—Pain—Cisplatin—esophageal cancer	0.00149	0.00235	CcSEcCtD
Entacapone—Vision blurred—Capecitabine—esophageal cancer	0.00148	0.00234	CcSEcCtD
Entacapone—Tremor—Capecitabine—esophageal cancer	0.00148	0.00232	CcSEcCtD
Entacapone—UGT1A9—Biological oxidations—CYP19A1—esophageal cancer	0.00146	0.00401	CbGpPWpGaD
Entacapone—Ill-defined disorder—Capecitabine—esophageal cancer	0.00146	0.0023	CcSEcCtD
Entacapone—Conjunctivitis—Methotrexate—esophageal cancer	0.00146	0.0023	CcSEcCtD
Entacapone—UGT1A9—Metapathway biotransformation—CYP19A1—esophageal cancer	0.00144	0.00395	CbGpPWpGaD
Entacapone—Sweating—Methotrexate—esophageal cancer	0.00144	0.00226	CcSEcCtD
Entacapone—Feeling abnormal—Cisplatin—esophageal cancer	0.00144	0.00226	CcSEcCtD
Entacapone—Haematuria—Methotrexate—esophageal cancer	0.00143	0.00225	CcSEcCtD
Entacapone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—esophageal cancer	0.00143	0.00391	CbGpPWpGaD
Entacapone—Malaise—Capecitabine—esophageal cancer	0.00142	0.00224	CcSEcCtD
Entacapone—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00142	0.00223	CcSEcCtD
Entacapone—Epistaxis—Methotrexate—esophageal cancer	0.00141	0.00223	CcSEcCtD
Entacapone—Vertigo—Capecitabine—esophageal cancer	0.00141	0.00223	CcSEcCtD
Entacapone—Syncope—Capecitabine—esophageal cancer	0.00141	0.00222	CcSEcCtD
Entacapone—Leukopenia—Capecitabine—esophageal cancer	0.00141	0.00222	CcSEcCtD
Entacapone—Agranulocytosis—Methotrexate—esophageal cancer	0.0014	0.0022	CcSEcCtD
Entacapone—Palpitations—Capecitabine—esophageal cancer	0.00139	0.00219	CcSEcCtD
Entacapone—Loss of consciousness—Capecitabine—esophageal cancer	0.00138	0.00218	CcSEcCtD
Entacapone—Body temperature increased—Cisplatin—esophageal cancer	0.00138	0.00217	CcSEcCtD
Entacapone—Cough—Capecitabine—esophageal cancer	0.00137	0.00216	CcSEcCtD
Entacapone—Hypertension—Capecitabine—esophageal cancer	0.00136	0.00214	CcSEcCtD
Entacapone—Haemoglobin—Methotrexate—esophageal cancer	0.00135	0.00213	CcSEcCtD
Entacapone—Hepatitis—Methotrexate—esophageal cancer	0.00135	0.00212	CcSEcCtD
Entacapone—Haemorrhage—Methotrexate—esophageal cancer	0.00135	0.00212	CcSEcCtD
Entacapone—Chest pain—Capecitabine—esophageal cancer	0.00134	0.00211	CcSEcCtD
Entacapone—Myalgia—Capecitabine—esophageal cancer	0.00134	0.00211	CcSEcCtD
Entacapone—Pharyngitis—Methotrexate—esophageal cancer	0.00134	0.0021	CcSEcCtD
Entacapone—Anxiety—Capecitabine—esophageal cancer	0.00134	0.0021	CcSEcCtD
Entacapone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00133	0.0021	CcSEcCtD
Entacapone—Urinary tract disorder—Methotrexate—esophageal cancer	0.00133	0.00209	CcSEcCtD
Entacapone—Discomfort—Capecitabine—esophageal cancer	0.00132	0.00209	CcSEcCtD
Entacapone—Urethral disorder—Methotrexate—esophageal cancer	0.00132	0.00208	CcSEcCtD
Entacapone—COMT—Metabolism—SLC52A3—esophageal cancer	0.00131	0.00359	CbGpPWpGaD
Entacapone—COMT—Metabolism—BLVRB—esophageal cancer	0.00131	0.00359	CbGpPWpGaD
Entacapone—Dry mouth—Capecitabine—esophageal cancer	0.00131	0.00206	CcSEcCtD
Entacapone—Visual impairment—Methotrexate—esophageal cancer	0.0013	0.00204	CcSEcCtD
Entacapone—Confusional state—Capecitabine—esophageal cancer	0.0013	0.00204	CcSEcCtD
Entacapone—Oedema—Capecitabine—esophageal cancer	0.00129	0.00202	CcSEcCtD
Entacapone—Hypersensitivity—Cisplatin—esophageal cancer	0.00128	0.00202	CcSEcCtD
Entacapone—Erythema multiforme—Methotrexate—esophageal cancer	0.00127	0.002	CcSEcCtD
Entacapone—Shock—Capecitabine—esophageal cancer	0.00126	0.00199	CcSEcCtD
Entacapone—Nervous system disorder—Capecitabine—esophageal cancer	0.00126	0.00198	CcSEcCtD
Entacapone—Eye disorder—Methotrexate—esophageal cancer	0.00126	0.00198	CcSEcCtD
Entacapone—Thrombocytopenia—Capecitabine—esophageal cancer	0.00126	0.00198	CcSEcCtD
Entacapone—Asthenia—Cisplatin—esophageal cancer	0.00125	0.00197	CcSEcCtD
Entacapone—Cardiac disorder—Methotrexate—esophageal cancer	0.00125	0.00197	CcSEcCtD
Entacapone—Skin disorder—Capecitabine—esophageal cancer	0.00125	0.00197	CcSEcCtD
Entacapone—Hyperhidrosis—Capecitabine—esophageal cancer	0.00124	0.00196	CcSEcCtD
Entacapone—Anorexia—Capecitabine—esophageal cancer	0.00123	0.00193	CcSEcCtD
Entacapone—UGT1A9—PPARA activates gene expression—CREBBP—esophageal cancer	0.00122	0.00335	CbGpPWpGaD
Entacapone—Hypotension—Capecitabine—esophageal cancer	0.0012	0.00189	CcSEcCtD
Entacapone—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CREBBP—esophageal cancer	0.0012	0.00328	CbGpPWpGaD
Entacapone—Diarrhoea—Cisplatin—esophageal cancer	0.00119	0.00188	CcSEcCtD
Entacapone—Alopecia—Methotrexate—esophageal cancer	0.00119	0.00187	CcSEcCtD
Entacapone—Mental disorder—Methotrexate—esophageal cancer	0.00118	0.00186	CcSEcCtD
Entacapone—Malnutrition—Methotrexate—esophageal cancer	0.00117	0.00185	CcSEcCtD
Entacapone—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00117	0.00184	CcSEcCtD
Entacapone—Insomnia—Capecitabine—esophageal cancer	0.00116	0.00183	CcSEcCtD
Entacapone—Paraesthesia—Capecitabine—esophageal cancer	0.00115	0.00182	CcSEcCtD
Entacapone—Dysgeusia—Methotrexate—esophageal cancer	0.00115	0.00181	CcSEcCtD
Entacapone—Dyspnoea—Capecitabine—esophageal cancer	0.00115	0.0018	CcSEcCtD
Entacapone—Back pain—Methotrexate—esophageal cancer	0.00113	0.00179	CcSEcCtD
Entacapone—Dyspepsia—Capecitabine—esophageal cancer	0.00113	0.00178	CcSEcCtD
Entacapone—Decreased appetite—Capecitabine—esophageal cancer	0.00112	0.00176	CcSEcCtD
Entacapone—COMT—Metabolism—SLC10A2—esophageal cancer	0.00111	0.00306	CbGpPWpGaD
Entacapone—COMT—Metabolism—CA1—esophageal cancer	0.00111	0.00306	CbGpPWpGaD
Entacapone—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00111	0.00175	CcSEcCtD
Entacapone—Vomiting—Cisplatin—esophageal cancer	0.00111	0.00175	CcSEcCtD
Entacapone—Fatigue—Capecitabine—esophageal cancer	0.00111	0.00174	CcSEcCtD
Entacapone—Vision blurred—Methotrexate—esophageal cancer	0.0011	0.00174	CcSEcCtD
Entacapone—Rash—Cisplatin—esophageal cancer	0.0011	0.00173	CcSEcCtD
Entacapone—Pain—Capecitabine—esophageal cancer	0.0011	0.00173	CcSEcCtD
Entacapone—Constipation—Capecitabine—esophageal cancer	0.0011	0.00173	CcSEcCtD
Entacapone—Dermatitis—Cisplatin—esophageal cancer	0.0011	0.00173	CcSEcCtD
Entacapone—Ill-defined disorder—Methotrexate—esophageal cancer	0.00109	0.00171	CcSEcCtD
Entacapone—Feeling abnormal—Capecitabine—esophageal cancer	0.00106	0.00167	CcSEcCtD
Entacapone—Malaise—Methotrexate—esophageal cancer	0.00106	0.00166	CcSEcCtD
Entacapone—Vertigo—Methotrexate—esophageal cancer	0.00105	0.00166	CcSEcCtD
Entacapone—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00105	0.00165	CcSEcCtD
Entacapone—Leukopenia—Methotrexate—esophageal cancer	0.00105	0.00165	CcSEcCtD
Entacapone—Nausea—Cisplatin—esophageal cancer	0.00104	0.00163	CcSEcCtD
Entacapone—Cough—Methotrexate—esophageal cancer	0.00102	0.00161	CcSEcCtD
Entacapone—Urticaria—Capecitabine—esophageal cancer	0.00102	0.00161	CcSEcCtD
Entacapone—COMT—Metabolism—CA2—esophageal cancer	0.00102	0.0028	CbGpPWpGaD
Entacapone—Abdominal pain—Capecitabine—esophageal cancer	0.00102	0.0016	CcSEcCtD
Entacapone—Body temperature increased—Capecitabine—esophageal cancer	0.00102	0.0016	CcSEcCtD
Entacapone—Convulsion—Methotrexate—esophageal cancer	0.00102	0.0016	CcSEcCtD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.00101	0.00278	CbGpPWpGaD
Entacapone—Myalgia—Methotrexate—esophageal cancer	0.000998	0.00157	CcSEcCtD
Entacapone—Chest pain—Methotrexate—esophageal cancer	0.000998	0.00157	CcSEcCtD
Entacapone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000991	0.00156	CcSEcCtD
Entacapone—Discomfort—Methotrexate—esophageal cancer	0.000986	0.00155	CcSEcCtD
Entacapone—Confusional state—Methotrexate—esophageal cancer	0.000965	0.00152	CcSEcCtD
Entacapone—COMT—Metabolism—PLCE1—esophageal cancer	0.000948	0.0026	CbGpPWpGaD
Entacapone—COMT—Metabolism—ADH7—esophageal cancer	0.000948	0.0026	CbGpPWpGaD
Entacapone—Hypersensitivity—Capecitabine—esophageal cancer	0.000947	0.00149	CcSEcCtD
Entacapone—Nervous system disorder—Methotrexate—esophageal cancer	0.000938	0.00148	CcSEcCtD
Entacapone—Thrombocytopenia—Methotrexate—esophageal cancer	0.000937	0.00147	CcSEcCtD
Entacapone—Skin disorder—Methotrexate—esophageal cancer	0.000929	0.00146	CcSEcCtD
Entacapone—Hyperhidrosis—Methotrexate—esophageal cancer	0.000925	0.00146	CcSEcCtD
Entacapone—Asthenia—Capecitabine—esophageal cancer	0.000922	0.00145	CcSEcCtD
Entacapone—Anorexia—Methotrexate—esophageal cancer	0.000912	0.00144	CcSEcCtD
Entacapone—Pruritus—Capecitabine—esophageal cancer	0.000909	0.00143	CcSEcCtD
Entacapone—Hypotension—Methotrexate—esophageal cancer	0.000894	0.00141	CcSEcCtD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000884	0.00242	CbGpPWpGaD
Entacapone—Diarrhoea—Capecitabine—esophageal cancer	0.000879	0.00138	CcSEcCtD
Entacapone—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000872	0.00137	CcSEcCtD
Entacapone—Insomnia—Methotrexate—esophageal cancer	0.000865	0.00136	CcSEcCtD
Entacapone—Paraesthesia—Methotrexate—esophageal cancer	0.000859	0.00135	CcSEcCtD
Entacapone—Dyspnoea—Methotrexate—esophageal cancer	0.000853	0.00134	CcSEcCtD
Entacapone—Somnolence—Methotrexate—esophageal cancer	0.000851	0.00134	CcSEcCtD
Entacapone—Dizziness—Capecitabine—esophageal cancer	0.00085	0.00134	CcSEcCtD
Entacapone—Dyspepsia—Methotrexate—esophageal cancer	0.000842	0.00133	CcSEcCtD
Entacapone—UGT1A9—PPARA activates gene expression—EP300—esophageal cancer	0.000833	0.00228	CbGpPWpGaD
Entacapone—Decreased appetite—Methotrexate—esophageal cancer	0.000832	0.00131	CcSEcCtD
Entacapone—COMT—Metabolism—ADH1B—esophageal cancer	0.000831	0.00228	CbGpPWpGaD
Entacapone—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000826	0.0013	CcSEcCtD
Entacapone—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—esophageal cancer	0.000825	0.00226	CbGpPWpGaD
Entacapone—Fatigue—Methotrexate—esophageal cancer	0.000825	0.0013	CcSEcCtD
Entacapone—Pain—Methotrexate—esophageal cancer	0.000818	0.00129	CcSEcCtD
Entacapone—Vomiting—Capecitabine—esophageal cancer	0.000817	0.00129	CcSEcCtD
Entacapone—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—esophageal cancer	0.000816	0.00224	CbGpPWpGaD
Entacapone—Rash—Capecitabine—esophageal cancer	0.00081	0.00128	CcSEcCtD
Entacapone—Dermatitis—Capecitabine—esophageal cancer	0.00081	0.00127	CcSEcCtD
Entacapone—Headache—Capecitabine—esophageal cancer	0.000805	0.00127	CcSEcCtD
Entacapone—COMT—Metabolism—TYMP—esophageal cancer	0.000794	0.00218	CbGpPWpGaD
Entacapone—Feeling abnormal—Methotrexate—esophageal cancer	0.000788	0.00124	CcSEcCtD
Entacapone—UGT1A9—Metabolism—BLVRB—esophageal cancer	0.000785	0.00215	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—SLC52A3—esophageal cancer	0.000785	0.00215	CbGpPWpGaD
Entacapone—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000782	0.00123	CcSEcCtD
Entacapone—COMT—Metabolism—CYP26A1—esophageal cancer	0.000773	0.00212	CbGpPWpGaD
Entacapone—Nausea—Capecitabine—esophageal cancer	0.000763	0.0012	CcSEcCtD
Entacapone—Urticaria—Methotrexate—esophageal cancer	0.00076	0.0012	CcSEcCtD
Entacapone—Abdominal pain—Methotrexate—esophageal cancer	0.000756	0.00119	CcSEcCtD
Entacapone—Body temperature increased—Methotrexate—esophageal cancer	0.000756	0.00119	CcSEcCtD
Entacapone—COMT—Metabolism—ALOX15—esophageal cancer	0.000753	0.00206	CbGpPWpGaD
Entacapone—COMT—Metabolism—GSTO1—esophageal cancer	0.000718	0.00197	CbGpPWpGaD
Entacapone—COMT—Metabolism—TPI1—esophageal cancer	0.000718	0.00197	CbGpPWpGaD
Entacapone—Hypersensitivity—Methotrexate—esophageal cancer	0.000705	0.00111	CcSEcCtD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000702	0.00192	CbGpPWpGaD
Entacapone—COMT—Metabolism—ALDOB—esophageal cancer	0.000689	0.00189	CbGpPWpGaD
Entacapone—Asthenia—Methotrexate—esophageal cancer	0.000686	0.00108	CcSEcCtD
Entacapone—Pruritus—Methotrexate—esophageal cancer	0.000677	0.00107	CcSEcCtD
Entacapone—UGT1A9—Metabolism—SLC10A2—esophageal cancer	0.000668	0.00183	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—CA1—esophageal cancer	0.000668	0.00183	CbGpPWpGaD
Entacapone—COMT—Metabolism—GAPDH—esophageal cancer	0.000663	0.00182	CbGpPWpGaD
Entacapone—COMT—Metabolism—CRABP1—esophageal cancer	0.000657	0.0018	CbGpPWpGaD
Entacapone—Diarrhoea—Methotrexate—esophageal cancer	0.000655	0.00103	CcSEcCtD
Entacapone—Dizziness—Methotrexate—esophageal cancer	0.000633	0.000996	CcSEcCtD
Entacapone—COMT—Metabolism—GNG7—esophageal cancer	0.000625	0.00171	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—CA2—esophageal cancer	0.000611	0.00167	CbGpPWpGaD
Entacapone—Vomiting—Methotrexate—esophageal cancer	0.000608	0.000958	CcSEcCtD
Entacapone—Rash—Methotrexate—esophageal cancer	0.000603	0.00095	CcSEcCtD
Entacapone—Dermatitis—Methotrexate—esophageal cancer	0.000603	0.000949	CcSEcCtD
Entacapone—Headache—Methotrexate—esophageal cancer	0.000599	0.000944	CcSEcCtD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000597	0.00164	CbGpPWpGaD
Entacapone—COMT—Metabolism—ALDH2—esophageal cancer	0.000586	0.00161	CbGpPWpGaD
Entacapone—Nausea—Methotrexate—esophageal cancer	0.000568	0.000895	CcSEcCtD
Entacapone—UGT1A9—Metabolism—PLCE1—esophageal cancer	0.000568	0.00156	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—ADH7—esophageal cancer	0.000568	0.00156	CbGpPWpGaD
Entacapone—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—esophageal cancer	0.000562	0.00154	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000561	0.00154	CbGpPWpGaD
Entacapone—COMT—Metabolism—GSTT1—esophageal cancer	0.000557	0.00153	CbGpPWpGaD
Entacapone—COMT—Metabolism—CYP2A6—esophageal cancer	0.000551	0.00151	CbGpPWpGaD
Entacapone—COMT—Metabolism—ENO1—esophageal cancer	0.000522	0.00143	CbGpPWpGaD
Entacapone—COMT—Metabolism—PTGS1—esophageal cancer	0.000522	0.00143	CbGpPWpGaD
Entacapone—COMT—Metabolism—PSME1—esophageal cancer	0.000514	0.00141	CbGpPWpGaD
Entacapone—COMT—Metabolism—PSME2—esophageal cancer	0.000514	0.00141	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—ADH1B—esophageal cancer	0.000498	0.00137	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—TYMP—esophageal cancer	0.000476	0.0013	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—CYP26A1—esophageal cancer	0.000463	0.00127	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—ALOX15—esophageal cancer	0.000451	0.00124	CbGpPWpGaD
Entacapone—COMT—Metabolism—CYP1B1—esophageal cancer	0.000444	0.00122	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—TPI1—esophageal cancer	0.00043	0.00118	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—GSTO1—esophageal cancer	0.00043	0.00118	CbGpPWpGaD
Entacapone—COMT—Metabolism—CYP19A1—esophageal cancer	0.000417	0.00114	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—ALDOB—esophageal cancer	0.000413	0.00113	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—GAPDH—esophageal cancer	0.000397	0.00109	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—CRABP1—esophageal cancer	0.000394	0.00108	CbGpPWpGaD
Entacapone—COMT—Metabolism—HMOX1—esophageal cancer	0.000381	0.00104	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—GNG7—esophageal cancer	0.000374	0.00103	CbGpPWpGaD
Entacapone—COMT—Metabolism—ABCB1—esophageal cancer	0.000365	0.001	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—ALDH2—esophageal cancer	0.000351	0.000962	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—GSTT1—esophageal cancer	0.000334	0.000915	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—CYP2A6—esophageal cancer	0.00033	0.000904	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000329	0.000901	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—PTGS1—esophageal cancer	0.000313	0.000857	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—ENO1—esophageal cancer	0.000313	0.000857	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—PSME2—esophageal cancer	0.000308	0.000845	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—PSME1—esophageal cancer	0.000308	0.000845	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000269	0.000738	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—CYP1B1—esophageal cancer	0.000266	0.000729	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—CYP19A1—esophageal cancer	0.00025	0.000685	CbGpPWpGaD
Entacapone—COMT—Metabolism—CREBBP—esophageal cancer	0.000244	0.00067	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—HMOX1—esophageal cancer	0.000228	0.000625	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	0.000224	0.000613	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—ABCB1—esophageal cancer	0.000219	0.0006	CbGpPWpGaD
Entacapone—COMT—Metabolism—NOS3—esophageal cancer	0.000219	0.0006	CbGpPWpGaD
Entacapone—COMT—Metabolism—PTGS2—esophageal cancer	0.0002	0.000548	CbGpPWpGaD
Entacapone—COMT—Metabolism—EP300—esophageal cancer	0.000166	0.000456	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	0.000166	0.000454	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—CREBBP—esophageal cancer	0.000146	0.000401	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—NOS3—esophageal cancer	0.000131	0.000359	CbGpPWpGaD
Entacapone—COMT—Metabolism—PIK3CA—esophageal cancer	0.000123	0.000337	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—PTGS2—esophageal cancer	0.00012	0.000328	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—EP300—esophageal cancer	9.97e-05	0.000273	CbGpPWpGaD
Entacapone—UGT1A9—Metabolism—PIK3CA—esophageal cancer	7.37e-05	0.000202	CbGpPWpGaD
